Drug Type Monoclonal antibody |
Synonyms MIL93 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrooesophageal junction cancer | Phase 1 | CN | 12 Jul 2022 | |
Metastatic Solid Tumor | Phase 1 | CN | 21 Apr 2021 | |
Pancreatic Cancer | Phase 1 | CN | - | |
CLDN18.2 Positive Gastrointestinal Neoplasms | IND Approval | CN | 29 Dec 2022 |
Phase 1 | 30 | nahwhboflx(nyweuxxddm) = krtnvzzexv pewiymdxkg (sitcmuaeoc ) View more | Positive | 24 Jan 2023 | |||
Phase 1 | 13 | rlpgtbinrq(pgdzdckoiq) = weiscpmgos njpzxwtprf (shyzutxqkk ) View more | Positive | 02 Jun 2022 |